Left: Daniel Hargrove, co-founder and CEO of InterAct Therapeutics; Right: Isaac Chan, MD, PhD, Co-founder and CSO of InterAct Therapeutics [Photos: LinkedIn]
InterAct, which launched inside BioLabs at Pegasus Park, is a preclinical stage biotech company developing AAV8-based gene therapies for metastatic cancer, with an initial focus on breast cancer-derived liver metastases.